Matthew Ros - See Remarks, Epizyme, Inc
As of August 18, 2021
Matthew Ros Net Worth
- Net worth is estimated to be at least $3.83M
- Owns at least 83,188 units of Epizyme, Inc stock
- Sold an estimated value of $3.8M in the last 5 years at Epizyme, Inc
Matthew Ros Compensation at Epizyme, Inc in 2020
- Earned a $447,982 salary
- Received a total compensation of $1,634,789
Matthew Ros Trading
- Largest purchase of shares was 112,003 units , worth over $1.06M on June 22, 2020
- Largest sale of shares was 112,003 units , worth over $2.38M on June 22, 2020
- In total has made about 16 transactions over 5 years
- Usually trades in February, with the busiest year in 2020
Matthew Ros
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
Matthew Ros Mailing Address
- Mailing address is C/o Epizyme, Inc. 400 Technology Square Cambridge MA 02139 MA
Epizyme, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Restricted Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Robert B. Bazemore Jr. | 2020 | $650,000 | - | $3,237,620 | $4,103,853 | $370,500 | $96,369 | $8,458,342 |
| Robert B. Bazemore Jr. | 2019 | $592,937 | - | $1,105,393 | $2,060,531 | $409,127 | $5,630 | $4,173,618 |
| Robert B. Bazemore Jr. | 2018 | $575,667 | - | - | $2,748,939 | $320,575 | $5,690 | $3,650,871 |
| Paolo Tombesi | 2020 | $460,000 | - | $250,006 | $750,730 | $174,800 | $48,198 | $1,683,734 |
| Paolo Tombesi | 2019 | $168,901 | - | $612,848 | $1,173,669 | $76,076 | $146,971 | $2,178,465 |
| Matthew E. Ros | 2020 | $447,982 | - | $250,006 | $750,730 | $174,800 | $11,271 | $1,634,789 |
| Matthew E. Ros | 2019 | $432,600 | - | $538,793 | $899,137 | $199,861 | $11,598 | $2,081,989 |
| Matthew E. Ros | 2018 | $420,000 | - | - | $1,099,576 | $187,100 | $12,214 | $1,718,890 |
| Dr. Shefali Agarwal | 2020 | $478,000 | - | $274,990 | $825,799 | $199,804 | $7,154 | $1,785,747 |
| Dr. Shefali Agarwal | 2019 | $463,500 | - | $894,607 | $1,255,325 | $265,122 | $8,652 | $2,887,206 |
| Dr. Shefali Agarwal | 2018 | $199,615 | $125,000 | - | $1,472,846 | $200,500 | $1,648 | $1,999,609 |
| Jeffery L. Kutok, M.D., Ph.D. | 2020 | $337,500 | $85,000 | $374,996 | $1,124,996 | $134,663 | $6,813 | $2,063,968 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1571498/000119312521138283/d839557ddef14a.htm
Epizyme, Inc Insider Trading
- The most recent transaction was 1,780 units sold on December 7, 2021 by Shefali Agarwal worth over $5.22K
- In the last 8 years, insiders at Epizyme, Inc sold an estimated value of $153.27M and bought an estimated value of $343.67M
- The most active traders are David Mott, Director, Robert Copeland, President Research and CSO, and Andrew Singer, EVP & CFO
- Insider trading is most common in June, with the busiest year in 2014
Epizyme, Inc. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||